# BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy

Calidi Biotherapeutics (NYSE American: CLDI) recently announced promising preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The innovative platform not only targets cancer cells effectively but also minimizes harm to surrounding healthy tissues, potentially improving treatment outcomes and reducing side effects. As global cancer rates continue to rise, Calidi’s RTNova platform and tumor-specific virotherapy hold the promise of offering new hope to cancer patients, addressing the limitations of existing treatments, and potentially improving survival rates across multiple cancer types. The company’s ongoing research and deep commitment to scientific excellence position it at the forefront of next-generation cancer care.

 To view the full article, visit https://ibn.fm/CvHqW

 About Calidi Biotherapeutics

 Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, visit the company’s website at www.calidibio.com.

 NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/biomednewsbreaks-calidi-biotherapeutics-inc-s-nyse-american-cldi-rtnova-shows-promise-in-targeted-tumor-therapy/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/calidi-biotherapeutics-reveals-breakthrough-in-cancer-treatment-delivery/9ecf976a6bc6adc828b81bd76b196f76) 

 



[Reddit Post](https://www.reddit.com/r/newsramp/comments/1kt4gm1/calidi_biotherapeutics_reveals_breakthrough_in/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/22/pearwfiH.webp)